CoChat

Sorafenib-induced defective autophagy promotes cell death by necroptosis

Open access
Kharaziha, Pedram, Chioureas, Dimitris, Baltatzis, George, Fonseca, Pedro, Rodriguez, Patricia, Gogvadze, Vladimir, Lennartsson, Lena, Björklund, Ann-Charlotte, Zhivotovsky, Boris, Grandér, Dan, Egevad, Lars, Nilsson, Sten, Panaretakis, Theocharis · 2015 · Oncotarget
Cited by 56

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

// Pedram Kharaziha 1 , Dimitris Chioureas 1 , George Baltatzis 2 , Pedro Fonseca 1 , Patricia Rodriguez 3 , Vladimir Gogvadze 4 , Lena Lennartsson 1 , Ann-Charlotte Björklund 1 , Boris Zhivotovsky 4 , Dan Grandér 1 , Lars Egevad 1 , Sten Nilsson 1 and Theocharis Panaretakis 1 1 Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet and University Hospital, Stockholm, Sweden 2 Department of Medicine, School of Health Sciences, University of Athens, Athens, Greece 3 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden 4 Institute of Environmental Medicine, Division of Toxicology, Karolinska Institutet, Stockholm, Sweden Correspondence to: Theocharis Panaretakis, email: // Keywords : prostate cancer, tyrosine kinase inhibitor, autophagy, Atg5, necroptosis Received : July 12, 2015 Accepted : August 29, 2015 Published : September 22, 2015 Abstract Autophagy is one of the main cytoprotective mechanisms that cancer cells deploy to withstand the cytotoxic stress and survive the lethal damage induced by anti-cancer drugs. However, under specific conditions, autophagy may, directly or indirectly, induce cell death. In our study, treatment of the Atg5-deficient DU145 prostate cancer cells, with the multi-tyrosine kinase inhibitor, sorafenib, induces mitochondrial damage, autophagy and cell death. Molecular inhibition of autophagy by silencing ULK1 and Beclin1 rescues DU145 cells from cell death indicating that, in this setting, autophagy promotes cell death. Re-expression of Atg5 restores the lipidation of LC3 and rescues DU145 and MEF atg5-/- cells from sorafenib-induced cell death. Despite the lack of Atg5 expression and LC3 lipidation, DU145 cells form autophagosomes as demonstrated by transmission and immuno-electron microscopy, and the formation of LC3 positive foci. However, the lack of cellular content in the autophagosomes, the accumulation of long-lived proteins, the presence of GFP-RFP-LC3 positive foci and the accumulated p62 protein levels indicate that these autophagosomes may not be fully functional. DU145 cells treated with sorafenib undergo a caspase-independent cell death that is inhibited by the RIPK1 inhibitor, necrostatin-1. Furthermore, treatment with sorafenib induces the interaction of RIPK1 with p62, as demonstrated by immunoprecipitation and a proximity ligation assay. Silencing of p62 decreases the RIPK1 protein levels and renders necrostatin-1 ineffective in blocking sorafenib-induced cell death. In summary, the formation of Atg5-deficient autophagosomes in response to sorafenib promotes the interaction of p62 with RIPK leading to cell death by necroptosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5797

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 56

Metadata

Authors
Kharaziha, P., Chioureas, D., Baltatzis, G., Fonseca, P., Rodriguez, P., Gogvadze, V., Lennartsson, L., Björklund, A.-C., Zhivotovsky, B., Grandér, D., Egevad, L., Nilsson, S., & Panaretakis, T.
Venue
Oncotarget
Published
2015-09-22
Volume
6
Issue
35
Pages
37066-37082
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1690731028
Cited by
56
References
14
FWCI
5.73
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.